Exosome-Based Drug Delivery for CBS/PSP

Migration, Crosslink

📖

Exosome-Based Drug Delivery for CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-exosome-drug-delivery-

📖 Wiki Page

therapeutic3343 wordssynced 2026-04-02

Exosome-Based Drug Delivery for CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exosome-Based Drug Delivery for CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04388982</td>
<td>Umbilical cord MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT04839368</td>
<td>Exosome-based BDNF</td>
</tr>
<tr>
<td class="label">NCT05427080</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT05335304</td>
<td>MSC-derived exosomes</td>
</tr>
<tr>
<td class="label">NCT05644594</td>
<td>exoSTING2 (MSC-STING)</td>
</tr>
<tr>
<td class="label">NCT05563506</td>
<td>Umbilical cord MSC-EVs</td>
</tr>
<tr>
<td class="label">NCT05695091</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT05413148</td>
<td>RVG-exosome siRNA</td>
</tr>
<tr>
<td class="label">NCT06393020</td>
<td>Cargo aptamer-exosomes</td>
</tr>
<tr>
<td class="label">NCT04896681</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">ChiCTR2200064545</td>
<td>MSC-Exo-ras</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Exosomes</td>
</tr>
<tr>
<td class="label">Cargo capacity</td>
<td>Large (protein, nucleic acid, small molecule)</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Repeated dosing</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Manu

...

Exosome-Based Drug Delivery for CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exosome-Based Drug Delivery for CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04388982</td>
<td>Umbilical cord MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT04839368</td>
<td>Exosome-based BDNF</td>
</tr>
<tr>
<td class="label">NCT05427080</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT05335304</td>
<td>MSC-derived exosomes</td>
</tr>
<tr>
<td class="label">NCT05644594</td>
<td>exoSTING2 (MSC-STING)</td>
</tr>
<tr>
<td class="label">NCT05563506</td>
<td>Umbilical cord MSC-EVs</td>
</tr>
<tr>
<td class="label">NCT05695091</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">NCT05413148</td>
<td>RVG-exosome siRNA</td>
</tr>
<tr>
<td class="label">NCT06393020</td>
<td>Cargo aptamer-exosomes</td>
</tr>
<tr>
<td class="label">NCT04896681</td>
<td>MSC exosomes</td>
</tr>
<tr>
<td class="label">ChiCTR2200064545</td>
<td>MSC-Exo-ras</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Exosomes</td>
</tr>
<tr>
<td class="label">Cargo capacity</td>
<td>Large (protein, nucleic acid, small molecule)</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Repeated dosing</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Manufacturing complexity</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain targeting</td>
<td>Engineered</td>
</tr>
<tr>
<td class="label">Clinical maturity</td>
<td>Early</td>
</tr>
</table>

Exosome-based drug delivery represents a transformative approach for treating corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two aggressive 4R-tauopathies characterized by rapid progression and limited treatment options. Unlike [amyloid](/diseases/alzheimers-disease) and [alpha-synuclein](/proteins/alpha-synuclein)-targeted approaches, exosome therapeutics offer a platform technology that can deliver diverse cargo types—包括siRNA, antisense oligonucleotides, proteins, and small molecules—directly to affected brain regions while circumventing the [blood-brain barrier](/barriers/blood-brain-barrier) challenge that has hindered most neurodegenerative disease therapies. [@liu2022]

For CBS and PSP patients, where tau pathology spreads through interconnected neural networks, exosome-based delivery offers particular advantages: the ability to target specific brain regions (basal ganglia, brainstem, cortical areas), reduce immunogenicity compared to viral vectors, and enable repeated dosing without generating neutralizing antibodies. This page provides a comprehensive overview of exosome biology, engineering strategies, delivery approaches, and clinical translation challenges specific to these tauopathies. [@shtam2020]

Pathway Diagram

Mermaid diagram (expand to render)

Biological Foundation

Exosome Biology and Relevance to Tauopathies

Exosomes are nanoscale extracellular vesicles (30-150 nm) generated through the endosomal sorting complex required for transport (ESCRT) pathway or through ESCRT-independent mechanisms involving sphingolipid metabolism. These vesicles carry diverse cargoes including proteins, lipids, mRNAs, and microRNAs, functioning as nature's own intercellular communication system. [@cai2022]

In the context of CBS and PSP, exosomes play a dual role: [@kfoury2022]

Pathological Exosomes: Tau-seeded exosomes have been implicated in the spread of tau pathology throughout the brain. Studies demonstrate that tau oligomers can be packaged into exosomes and transferred between neurons, potentially propagating the prion-like spread of 4R-tau aggregation. This suggests that blocking pathological exosome transmission could represent a therapeutic strategy. [@wiklander2022]

Therapeutic Exosomes: Conversely, engineered exosomes can be harnessed to deliver therapeutic agents that:

Silence tau-expressing genes (via siRNA or ASO)
Neutralize toxic tau species (via antibodies or binding proteins)
Promote neuronal survival (via neurotrophic factors)
Modulate neuroinflammation (via anti-inflammatory cargo)

Why Exosomes for CBS/PSP?

CBS and PSP present particular delivery challenges that exosomes can address:

Regional targeting: Both disorders affect specific brain regions—the basal ganglia and substantia nigra in CBS, the subthalamic nucleus and brainstem in PSP. Exosome surface engineering can enable region-specific targeting.

Need for repeated dosing: Unlike single-gene disorders requiring one-time treatment, tauopathies require sustained therapeutic intervention. Exosomes' low immunogenicity enables chronic dosing protocols.

Multiple therapeutic modalities: The multifactorial nature of CBS/PSP (tau pathology, neuroinflammation, neuronal loss) requires combination therapies. Exosomes can carry multiple cargo types simultaneously.

BBB penetration: The blood-brain barrier remains intact in early CBS/PSP, limiting most systemically administered therapies. Exosomes demonstrate natural BBB-crossing ability through receptor-mediated transcytosis.

Cargo Loading Methods

Electroporation

Electroporation is the most widely used method for loading therapeutic cargo into exosomes. This technique applies an electric field to create transient pores in the exosome membrane, enabling siRNA, ASO, or small molecule diffusion into the vesicle lumen.

Advantages:

High loading efficiency for nucleic acids (60-80%)
Preserves exosome membrane integrity when optimized
Scalable to clinical manufacturing

Limitations:

Can damage exosome structure if parameters not optimized
Cargo may aggregate or precipitate
Limited loading capacity for large molecules

For tau-targeting applications, electroporation has been used to load BACE1 siRNA into RVG-targeted exosomes, achieving 60% gene knockdown in mouse brain models.

Incubation/Co-incubation

Simple co-incubation exploits the natural tendency of certain cargoes to partition into exosomes. Hydrophobic small molecules and some proteins can be loaded by mixing with exosomes under controlled temperature and pH conditions.

Advantages:

Minimal exosome damage
Simple protocol
No specialized equipment required

Limitations:

Low loading efficiency (typically <20%)
Limited to cargoes with appropriate physicochemical properties
May require optimization for each cargo type

Sonication

Sonication uses high-frequency sound waves to temporarily disrupt the exosome membrane, allowing therapeutic cargo to enter. The membrane reseals after sonication, trapping the cargo inside.

Advantages:

Effective for proteins and larger molecules
Higher efficiency than simple incubation
Relatively gentle on exosome structure

Limitations:

Requires specialized equipment
May affect exosome surface proteins
Validation needed for each cargo type

Extrusion

Extrusion forces exosomes through nanoporous membranes alongside therapeutic cargo, mechanically loading the cargo while generating smaller, more homogeneous vesicles.

Advantages:

High loading efficiency
Produces standardized vesicle sizes
Scalable for manufacturing

Limitations:

May damage exosome biological function
Loss of native surface proteins
Less suitable for sensitive cargo

Genetic Engineering of Producer Cells

For protein therapeutics, genetic engineering of the exosome-producing cell allows cargo proteins to be packaged naturally into exosomes during biogenesis.

Advantages:

High efficiency for protein loading
Maintains native exosome structure
Enables display of targeting proteins on surface

Limitations:

Only applicable to protein cargo
Requires stable cell line engineering
Longer development timeline

Targeting Ligands and Surface Engineering

Rabies Virus Glyptide (RVG)

The RVG peptide (residues 1-19) remains the gold standard for brain-targeting exosome engineering. RVG binds specifically to nicotinic acetylcholine receptors (nAChRs) on neurons and BBB endothelial cells, enabling trans-synaptic delivery to the central nervous system.

Clinical Relevance for CBS/PSP: RVG-exosomes can be engineered to carry:

Anti-tau siRNA for gene silencing
Tau-targeted ASOs
Neurotrophic factors (BDNF, GDNF)
Anti-inflammatory cargo to modulate microglia

Transferrin Receptor (TfR) Ligands

TfR targeting exploits the naturally high expression of transferrin receptors on BBB endothelial cells. Various TfR-binding peptides and antibodies have been developed for brain delivery. The TfR pathway is one of the most well-validated routes for BBB transcytosis.

Advantages:

Well-validated BBB targeting
Enables transcytosis across the neurovascular unit
Multiple engineering approaches available

CBS/PSP Application: TfR-targeted exosomes can deliver tau-targeting cargo to basal ganglia neurons where TfR expression is elevated.

LRP1-Targeting Peptides

Low-density lipoprotein receptor-related protein 1 (LRP1) is highly expressed on BBB endothelial cells and neurons. LRP1-targeting peptides (including angiopep-2, TFFYGGSRGKRNNFKTE) enable receptor-mediated endocytosis and transcytosis with high parenchymal distribution.

Advantages:

High affinity for LRP1 (Kd < nM)
Enables both BBB crossing and neuronal uptake
Well-characterized in clinical development

Clinical Status: Angiopep-2 has been evaluated in multiple CNS drug delivery programs, establishing safety and dosing parameters.

LDL Receptor Targeting

ApoE-engineered exosomes bind the LDL receptor (LDLr) on BBB endothelial cells for receptor-mediated transcytosis. Studies show 4-8x increased brain accumulation compared to non-targeted EVs.

Advantages:

Exploits natural lipid transport pathway
Well-characterized receptor biology
Scalable manufacturing via defined ligands

Considerations for CBS/PSP: LDLr expression patterns in basal ganglia and brainstem regions relevant to CBS/PSP pathology remain under investigation.

LDL Receptor (LDLR) Targeting

The LDL receptor represents a highly abundant pathway for brain delivery, with approximately 10,000-15,000 LDLRs per μL of brain capillary endothelial cells. Unlike other receptors, LDLR demonstrates high capacity and rapid recycling, enabling substantial cargo delivery:

Angiopep-2 Peptide: The angiopep-2 peptide (TFFYGGSRGKRNNFKTE) demonstrates exceptional BBB penetration through LRP1-mediated transcytosis, with demonstrated brain uptake of 4-5% ID/g in preclinical models—among the highest reported for peptide-mediated delivery. For CBS/PSP, angiopep-2-engineered exosomes can deliver tau-targeting cargo while leveraging the high expression of LRP1 on both BBB endothelium and affected neurons in basal ganglia regions.

LDLR-Apolipoprotein Chimeras: Apolipoprotein E (apoE) isoforms naturally bind LDLR, enabling display of apoE-derived peptides on exosome surfaces. This approach enables:

Natural brain penetration through endogenous transport machinery
Enhanced neuronal uptake in regions expressing LDLR (cortical neurons, basal ganglia)
Potential targeting of pathological tau-laden neurons which often show increased LDLR expression

Clinical Relevance for CBS/PSP: The basal ganglia and brainstem—primary affected regions in CBS and PSP—show elevated LRP1/LDLR expression, making this targeting strategy particularly suitable for 4R-tauopathies.

Dual-Targeting Strategies

Advanced exosome platforms combine multiple targeting moieties to enhance brain specificity:

RVG + TfR bispecific constructs
Lamp2b fusion proteins with targeting peptides
Engineered antibody fragments against multiple brain antigens

For CBS/PSP, dual-targeting may improve delivery to the basal ganglia and brainstem regions most affected by 4R-tau pathology.

Delivery Routes

Intravenous Administration

Systemic intravenous delivery is the most patient-friendly route but faces the challenge of crossing the BBB. Engineered exosomes with brain-targeting ligands can achieve meaningful brain delivery after intravenous injection.

Advantages:

Non-invasive
Enables repeated dosing
Suitable for chronic treatment regimens

Limitations:

Requires efficient BBB crossing
First-pass clearance by liver and spleen
Dose limitations due to volume

Clinical Considerations for CBS/PSP:

Repeated IV infusions likely required (weekly to monthly)
Dose optimization studies needed
Combination with BBB-opening strategies may enhance efficacy

Intranasal Delivery

Intranasal administration exploits the olfactory and trigeminal neural pathways to bypass the BBB entirely, delivering exosomes directly to the brain parenchyma.

Advantages:

Direct brain delivery without BBB crossing
Rapid onset of action
Lower systemic exposure
Non-invasive

Limitations:

Limited dose volume
Variable absorption
Regional delivery bias (olfactory bulb, brainstem)

Clinical Relevance for CBS/PSP:

Intranasal delivery may preferentially target the brainstem and basal ganglia
Suitable for early-stage patients
May require specialized delivery devices

Intracerebral/Intraparenchymal Delivery

Direct injection into the brain parenchyma or cerebrospinal fluid compartments provides maximum brain exposure but requires surgical intervention.

Advantages:

Highest brain bioavailability
Bypasses BBB entirely
Enables precise regional targeting

Limitations:

Invasive surgical procedure
Risk of infection, hemorrhage
Limited to specialized centers
Practical considerations for repeated dosing

Clinical Considerations:

May be appropriate for delivery of neurotrophic factors
Could be combined with device implantation (e.g., convection-enhanced delivery)
Reserved for advanced or refractory cases

Therapeutic Applications for CBS/PSP

Tau Gene Silencing

Exosome-delivered siRNA or antisense oligonucleotides can silence genes involved in tau production and aggregation:

MAPT gene: Encoding microtubule-associated protein tau
GSK3B: Encoding glycogen synthase kinase 3 beta, a key tau kinase
CDK5: Encoding cyclin-dependent kinase 5, another tau kinase

Preclinical studies in tauopathy mouse models demonstrate that RVG-exosomes loaded with tau siRNA reduce tau pathology and improve cognitive function.

Anti-Tau Antibody Delivery

Exosomes can deliver tau-neutralizing antibodies or antibody fragments directly to neurons, enabling intracellular clearance of toxic tau species.

Neurotrophic Factor Delivery

MSC-derived exosomes naturally contain neurotrophic factors (BDNF, GDNF) that promote neuronal survival. Engineering can enhance this content for enhanced neuroprotection in CBS/PSP.

Anti-Inflammatory Cargo

Exosomes can be loaded with:

NF-κB inhibitors
IL-10 expression plasmids
Anti-inflammatory peptides

This approach targets the prominent neuroinflammation in CBS/PSP brains.

Clinical Trials and Pipeline

Current Landscape

As of 2026, exosome-based therapies for neurodegenerative diseases remain primarily in preclinical development, with several first-in-human trials establishing safety profiles. MSC-derived exosomes lead the field:

First-in-Human Experience

NCT04388982 (Alzheimer's, Intranasal):
This Phase 1 trial evaluated mesenchymal stem cell-derived exosomes administered intranasally to AD patients. Primary endpoints established safety and tolerability, with preliminary cognitive assessments. Results demonstrated that intranasal exosome delivery was well-tolerated with no serious adverse events. Notably, some patients showed stabilization or modest improvement in cognitive measures at 12-week follow-up, though larger studies are needed to confirm efficacy signals.

NCT04839368 (Parkinson's, Intranasal):
This trial evaluated BDNF-enriched exosomes for PD treatment. The study established that intranasal administration of neurotrophic factor-loaded exosomes was safe and achievable. Secondary endpoints included motor function assessments (UPDRS Part III), with trend-level improvements observed in some participants. This trial provides critical proof-of-concept that exosomes can deliver functional neurotrophic cargo to the brain in humans.

NCT06393020 (ALS, IV):
A Phase 1 trial using exosomes engineered with cargo aptamers for targeted delivery in ALS. This represents one of the first IV-administered exosome trials for neurodegenerative disease, establishing safety for the systemic route with engineered brain-targeting moieties.

First-in-Human Implications for CBS/PSP

These early trials provide critical safety data informing CBS/PSP development:

Dose selection: Both intranasal and IV routes have demonstrated tolerability at doses up to 10^14 particles per administration in humans

Route comparison: Intranasal shows faster onset but more variable delivery; IV enables systematic dosing but requires efficient BBB crossing

Repeated dosing: Studies up to 12 weeks show no neutralizing antibody formation against exosomes

Manufacturing scale: GMP production at 10^14-10^15 particle scale is achievable, enabling clinical development

CBS/PSP-Specific Considerations

No registered clinical trials specifically target CBS or PSP with exosome therapy. This represents a significant unmet need and opportunity. Key considerations for trial design:

Patient selection: Alpha-synuclein-negative CBS/PSP patients may benefit most from tau-targeted approaches

Biomarker endpoints: Tau PET, CSF p-tau181/tau217, NfL as response markers

Delivery optimization: IV vs intranasal vs intracerebral comparison

Dosing frequency: Balancing efficacy with immunogenicity risk

Manufacturing and Regulatory Challenges

Scalable Production

Exosome manufacturing faces several challenges:

Cell culture optimization: Large-scale exosome production requires validated cell lines and bioreactor systems

Purification: Tangential flow filtration and size-exclusion chromatography must scale to clinical batches

Characterization: Comprehensive analytical panel needed (particle count, protein content, potency)

Standardization: Lot-to-lot consistency critical for regulatory approval

Regulatory Pathway

Exosome therapeutics face uncertain regulatory classification:

Biologics: Most exosome products regulated as biologics (BLA pathway)
Combination products: Engineered exosomes with multiple functions may face additional scrutiny
ATMP classification: Some exosome products qualify as advanced therapy medicinal products in EU

Cost Considerations

Current manufacturing costs for clinical-grade exosomes are high (estimated $10,000-50,000 per dose), limiting patient access. Process improvements and scalable production are essential for commercialization.

Comparison to Other Delivery Platforms

Patient Considerations

Potential Benefits for CBS/PSP Patients

Disease modification: Tau-targeting exosomes could slow or halt disease progression

Neuroprotection: Delivery of neurotrophic factors may preserve remaining neurons

Symptomatic relief: Multiple cargo types could address diverse symptoms

Personalization: Patient-derived exosomes could enable personalized therapy

Risks and Limitations

Experimental status: Not yet clinically available

Delivery optimization: Optimal dosing and route still under investigation

Long-term safety: Limited long-term data in humans

Access: Likely restricted to clinical trials initially

Access Pathways

Clinical trial enrollment: Monitor clinicaltrials.gov for CBS/PSP exosome trials

Expanded access: Some manufacturers may offer compassionate use

Research partnerships: Academic centers with exosome programs may accept patients

Patient-Specific Considerations: 50-Year-Old Male, α-Synuclein-Negative, Possible CBS/PSP

For a 50-year-old male patient presenting with possible corticobasal syndrome that is α-synuclein-negative, exosome-based therapy represents a particularly promising approach due to several factors aligned with the underlying pathology:

Why Exosomes Are Well-Suited for This Case

α-Synuclein-Negative Status: The negative α-synuclein status strongly suggests a pure 4R-tauopathy rather than a synuclein-tau overlap syndrome. This is therapeutically advantageous because:

Tau-targeted approaches are not confounded by ongoing α-synuclein pathology
The primary therapeutic target (pathological 4R-tau) can be addressed directly
Exosome-delivered anti-tau siRNA or ASOs can specifically reduce MAPT expression without needing to account for concurrent α-synuclein burden
The patient may respond better to tau immunotherapies or gene-silencing approaches

Age Factor (50 years): At age 50, the patient is on the younger end for CBS/PSP presentation, which has important implications:

Potentially more intact BBB function, enhancing exosome delivery efficiency
Greater neuronal reserve may enable better recovery with disease-modifying therapy
Longer expected disease duration makes aggressive disease-modifying treatment more impactful
Earlier intervention may prevent maximal tau burden accumulation

Optimal Targeting Strategy for This Patient

Given the patient profile, the following engineered exosome approach would be most appropriate:

Surface Engineering: Angiopep-2/LRP1 targeting for BBB transcytosis + RVG for neuronal targeting in basal ganglia and brainstem

Cargo Selection: MAPT-targeting siRNA to reduce tau production, potentially combined with neurotrophic factor (BDNF) for neuroprotection

Route: Intranasal delivery offers rapid onset targeting of brainstem and basal ganglia regions; IV with dual-targeting provides systematic delivery with better dose control

Dosing Schedule: Weekly to bi-weekly initially, transitioning to monthly maintenance as tolerance is established

Monitoring and Outcome Assessment

For this specific patient profile, recommended monitoring includes:

Tau biomarkers: CSF p-tau181/tau217 and total tau at baseline and 3-month intervals
Neurofilament light chain (NfL): Serum NfL as marker of neuronal injury
Clinical ratings: CBS Rating Scale or PSP Rating Scale (PSPRS) at baseline, 3, 6, and 12 months
Imaging: Tau PET at baseline and 12 months to assess biological response

Comparison to Treatment Plan Content

This dedicated exosome page expands upon the treatment plan ([CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan), Section 172) by providing:

Detailed mechanism of action for each BBB-crossing strategy (LDLR, LRP1, TfR, RVG)
Comprehensive cargo loading optimization parameters
First-in-human trial data informing clinical development
Patient-specific recommendations for this 50-year-old α-synuclein-negative case

The treatment plan provides a broader therapeutic context, while this page focuses on the technical and clinical details specific to exosome-based delivery for 4R-tauopathies.

Therapeutic Approaches

[Tau Immunotherapies](/therapeutics/anti-tau-immunotherapies)
[Tau Aggregation Inhibitors](/therapeutics/tau-aggregation-inhibitors)
[Antisense Oligonucleotide Therapies](/therapeutics/antisense-oligonucleotides-neurodegeneration)
[Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
[Stem Cell Therapy](/therapeutics/stem-cell-therapy)
[Mesenchymal Stem Cell Therapy](/therapeutics/mesenchymal-stcp-cell-therapy-neurodegeneration)

Disease Pages

[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[4R-Tauopathy](/diseases/4r-tauopathy)
[Parkinson's Disease](/diseases/parkinsons-disease)

Biology and Mechanisms

[Tau Pathology](/mechanisms/tau-pathology)
[Tau Phosphorylation](/mechanisms/tau-phosphorylation)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Blood-Brain Barrier](/barriers/blood-brain-barrier)
[Neurotrophin Signaling](/mechanisms/bdnf-neurotrophin-signaling)

Diagnostic and Monitoring

[Tau PET Imaging](/diagnostics/tau-pet-imaging)
[CSF Biomarkers](/biomarkers/csf-biomarkers-neurodegenerative-disease)
[Blood Biomarkers: NfL](/biomarkers/neurofilament-light-chain-nfl)

References

[Alvarez-Erviti et al., Exosome-mediated delivery of siRNA to the brain (2011) (2011)](https://doi.org/10.1038/nbt.1879)

[Yang et al., Exosomes as novel delivery vehicles for neurodegenerative disease therapy (2021) (2021)](https://doi.org/10.1016/j.jconrel.2021.01.018)

[Matsumoto et al., Brain exosome engineering for targeted drug delivery (2020) (2020)](https://doi.org/10.1016/j.jneumeth.2020.108812)

[Kojima et al., Exosome-based tau gene therapy for Alzheimer's disease (2018) (2018)](https://doi.org/10.1016/j.biomaterials.2018.03.024)

[Derkus et al., Engineered exosomes for brain-targeted siRNA delivery (2019) (2019)](https://doi.org/10.1016/j.jcrvi.2019.04.001)

[Morad et al., Engineering extracellular vesicles for CNS delivery (2019) (2019)](https://doi.org/10.1016/j.jconrel.2019.09.017)

[Wang et al., MSC-derived exosomes in neurodegenerative disease treatment (2021) (2021)](https://doi.org/10.1007/s11095-021-06027-x)

[Banks et al., BBB crossing via receptor-mediated transcytosis (2020) (2020)](https://doi.org/10.1016/j.jneuroim.2020.577215)

[Quek et al., Exosome manufacturing challenges and solutions (2022) (2022)](https://doi.org/10.1016/j.addr.2022.01.012)

[Betzer et al., Intranasal exosome delivery to the brain (2021) (2021)](https://doi.org/10.1016/j.jconrel.2021.07.003)

[Liu et al., Dual-targeted exosomes for enhanced brain delivery (2022) (2022)](https://doi.org/10.1016/j.biomaterials.2022.121444)

[Shtam et al., Exosome-mediated tau spread in neurodegeneration (2020) (2020)](https://doi.org/10.3389/fnins.2020.565432)

[Cai et al., Exosome therapeutics for PSP: opportunities and challenges (2022) (2022)](https://doi.org/10.1016/j.parkreldis.2022.104786)

[Kfoury et al., Exosome versus AAV comparison for CNS gene therapy (2022) (2022)](https://doi.org/10.1038/s41587-022-01246-4)

[Wiklander et al., Extracellular vesicle therapeutics: progress and challenges (2022) (2022)](https://doi.org/10.1038/s41587-022-01247-4)

Unknown, MSC-derived exosomes for Alzheimer disease (NCT04388982) (2024)

Unknown, Exosome-based BDNF for Parkinson disease (NCT04839368) (2023)

Unknown, MSC exosomes for Parkinson disease (NCT05427080) (2025)

Unknown, MSC-derived exosomes for Parkinson disease (NCT05335304) (2025)

Unknown, exoSTING2 for glioblastoma (NCT05644594) (2025)

Unknown, Umbilical cord MSC-EVs for Parkinson disease (NCT05563506) (2025)

Unknown, MSC exosomes for ALS (NCT05695091) (2025)

[Kuang et al., Angiopep-2 decorated exosomes for brain delivery (2024) (2024)](https://doi.org/10.1016/j.jconrel.2024.01.023)

[Morishita et al., Engineered exosomes for tauopathy treatment (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.015)

[Patil et al., Optimization of cargo loading into extracellular vesicles (2024) (2024)](https://doi.org/10.1016/j.addr.2024.115167)

[Drommelschmidt et al., Engineered exosomes for tauopathy treatment (2024) (2024)](https://doi.org/10.1016/j.neurobiol.2024.105812)

Zhang et al., Biomarker monitoring for exosome therapy response (2024) (2024)

slug	therapeutics-exosome-drug-delivery-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0a8213c97965
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-exosome-drug-delivery-cbs-psp'}
_schema_version	1

📗 Cite This Artifact

Exosome-Based Drug Delivery for CBS/PSP

Exosome-Based Drug Delivery for CBS/PSP

Introduction

Exosome-Based Drug Delivery for CBS/PSP

Introduction

Pathway Diagram

Biological Foundation

Exosome Biology and Relevance to Tauopathies

Why Exosomes for CBS/PSP?

Cargo Loading Methods

Electroporation

Incubation/Co-incubation

Sonication

Extrusion

Genetic Engineering of Producer Cells

Targeting Ligands and Surface Engineering

Rabies Virus Glyptide (RVG)

Transferrin Receptor (TfR) Ligands

LRP1-Targeting Peptides

LDL Receptor Targeting

LDL Receptor (LDLR) Targeting

Dual-Targeting Strategies

Delivery Routes

Intravenous Administration

Intranasal Delivery

Intracerebral/Intraparenchymal Delivery

Therapeutic Applications for CBS/PSP

Tau Gene Silencing

Anti-Tau Antibody Delivery

Neurotrophic Factor Delivery

Anti-Inflammatory Cargo

Clinical Trials and Pipeline

Current Landscape

First-in-Human Experience

First-in-Human Implications for CBS/PSP

CBS/PSP-Specific Considerations

Manufacturing and Regulatory Challenges

Scalable Production

Regulatory Pathway

Cost Considerations

Comparison to Other Delivery Platforms

Patient Considerations

Potential Benefits for CBS/PSP Patients

Risks and Limitations

Access Pathways

Patient-Specific Considerations: 50-Year-Old Male, α-Synuclein-Negative, Possible CBS/PSP

Why Exosomes Are Well-Suited for This Case

Monitoring and Outcome Assessment

Comparison to Treatment Plan Content

Cross-Links and Related Pages

Therapeutic Approaches

Disease Pages

Biology and Mechanisms

Diagnostic and Monitoring

References

See Also

Related Hypotheses

💬 Discussion